{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:56:48Z","timestamp":1761764208216},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.dld.2003.11.018","type":"journal-article","created":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T11:00:20Z","timestamp":1072782020000},"page":"S86-S92","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Somatostatin receptors: from basic science to clinical approach\u2014thyroid"],"prefix":"10.1016","volume":"36","author":[{"given":"M.C","family":"Zatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C","family":"degli Uberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2003.11.018_BIB1","first-page":"297","article-title":"C-cell hyperplasia accompanying thyroid disease other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin","volume":"4","author":"Scopsi","year":"1991","journal-title":"Mol. Pathol."},{"key":"10.1016\/j.dld.2003.11.018_BIB2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1210\/jc.82.6.1857","article-title":"Somatostatin receptor subtype expression in human thyroid carcinoma cell lines","volume":"82","author":"Ain","year":"1997","journal-title":"J. Clin. Metab. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB3","first-page":"636","article-title":"111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors","volume":"41","author":"Forssell-Aronsson","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF02067319","article-title":"Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue","volume":"16","author":"Siperstein","year":"1992","journal-title":"World J. Surg."},{"key":"10.1016\/j.dld.2003.11.018_BIB5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1210\/jcem-47-5-1156","article-title":"Somatostatin inhibits thyroid hormone secretion induced by exogenous TSH in man","volume":"47","author":"Ahren","year":"1978","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2265.1986.tb01663.x","article-title":"Effects of somatostatin analogie SMS 201-995 in normal man","volume":"24","author":"Davies","year":"1986","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1530\/eje.0.1330430","article-title":"Effects of treatment with octreotide in acromegalic patients\u2014a multicenter Italian study. Italian Multicenter Octreotide Study Group","volume":"133","author":"Arosio","year":"1995","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/eje.0.1330189","article-title":"Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non functioning pituitary adenomas","volume":"133","author":"Colao","year":"1995","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1210\/jc.82.1.23","article-title":"Sandostatin LAR in acromegalic patients: long term treatment","volume":"82","author":"Kvistborg Flogstad","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1210\/jc.81.6.2089","article-title":"Effectiveness and tolerability of slow release Lanreotide treatment in active acromegaly: six month report on an Italian Multicenter study","volume":"81","author":"Giusti","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.82.1.18","article-title":"Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide","volume":"82","author":"Caron","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1055\/s-0038-1629763","article-title":"Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy","volume":"34","author":"Becker","year":"1995","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.dld.2003.11.018_BIB13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00003072-199709000-00009","article-title":"Uptake of 111In-pentreotide by normally functioning nodular goiters","volume":"22","author":"Garancini","year":"1997","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.bjc.6690251","article-title":"Expression of somatostatin receptors in oncocytic (Hurtle cell) neoplasia of the thyroid","volume":"79","author":"Tisell","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.dld.2003.11.018_BIB15","first-page":"127","article-title":"111In-octreotide in the evaluation of autoimmune thyroid disease","volume":"39","author":"Mansi","year":"1995","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1210\/jcem-72-6-1364","article-title":"Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro","volume":"72","author":"degli Uberti","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1210\/jc.78.5.1097","article-title":"Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro","volume":"78","author":"Ain","year":"1994","journal-title":"J. Clin. Metab. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB18","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1074\/jbc.271.11.6129","article-title":"Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable transfections of E1A viral oncogene","volume":"271","author":"Florio","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.dld.2003.11.018_BIB19","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1210\/en.138.9.3756","article-title":"Oncogene transformation of PC C13 clonal thyroid cell line induces an autonomous pattern of proliferation that correlates with a loss of basal and stimulated phosphotyrosine phosphatase activity","volume":"138","author":"Florio","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.dld.2003.11.018_BIB20","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/me.15.10.1838","article-title":"The activation of the Phosphotyrosine Phosphatase \u03b7 (r-PTP\u03b7) is responsible for the somatostatin inhibition of PC C13 thyroid cell proliferation","volume":"15","author":"Florio","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB21","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1210\/endo-126-6-3131","article-title":"Somatostatin inhibit DNA synthesis induced by both thyrotropin and insulin-like growth factor in FRTL-5 cells","volume":"126","author":"Tsuzaki","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.dld.2003.11.018_BIB22","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1074\/jbc.275.20.15549","article-title":"Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol3-kinase. Involvement of RhoA and cyclinExCyclin-dependent kinase2 complexes","volume":"275","author":"Medina","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.dld.2003.11.018_BIB23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1210\/en.140.1.87","article-title":"Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down regulation of the cyclin-dependent kinase inhibitor p27kip1","volume":"140","author":"Medina","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.dld.2003.11.018_BIB24","first-page":"807","article-title":"Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma","volume":"36","author":"Tenenbaum","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000201391","article-title":"Somatostatin receptor scintigraphy in non-medullary thyroid cancer","volume":"57","author":"Postema","year":"1996","journal-title":"Digestion"},{"key":"10.1016\/j.dld.2003.11.018_BIB26","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/jc.81.7.2541","article-title":"Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan","volume":"81","author":"Baudin","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s002590050270","article-title":"The use of indium-111 pentreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake","volume":"25","author":"Garin","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF03351041","article-title":"Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer","volume":"24","author":"Haslinghuis","year":"2001","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.dld.2003.11.018_BIB29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/105072501750362718","article-title":"Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer","volume":"11","author":"Gorges","year":"2001","journal-title":"Thyroid"},{"key":"10.1016\/j.dld.2003.11.018_BIB30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/thy.1994.4.427","article-title":"Octreotide therapy in advanced thyroid cancer","volume":"4","author":"Zlock","year":"1994","journal-title":"Thyroid"},{"key":"10.1016\/j.dld.2003.11.018_BIB31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2000.10.177","article-title":"Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue","volume":"10","author":"Robbins","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.dld.2003.11.018_BIB32","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1023\/A:1027396313397","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.dld.2003.11.018_BIB33","first-page":"567","article-title":"Somatostatin receptors and somatostatin content in medullary thyroid carcinomas","volume":"64","author":"Reubi","year":"1991","journal-title":"Lab. Invest."},{"key":"10.1016\/j.dld.2003.11.018_BIB34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"Molecular properties of somatostatin and its analogs in the diagnosis and treatment of tumors","volume":"12","author":"Lamberts","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.dld.2003.11.018_BIB35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1210\/jc.76.6.1413","article-title":"In vivo somatostatin receptor imaging in medullary thyroid carcinoma","volume":"76","author":"Kwekkeboom","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0969-8051(96)00031-5","article-title":"Combined use of 111In-DTPA-D-Phe-1-Octreotide (OCT) and 123I-Vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC)","volume":"23","author":"Kurtaran","year":"1996","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.dld.2003.11.018_BIB37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006231-199609000-00013","article-title":"Somatostatin and somatostatin analogues in medullary thyroid carcinoma","volume":"17","author":"O\u2019Byrne","year":"1996","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.dld.2003.11.018_BIB38","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2436::AID-CNCR16>3.0.CO;2-D","article-title":"Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma","volume":"80","author":"Behr","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2003.11.018_BIB39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/bjs.1800840431","article-title":"Somatostatin receptor scintigraphy in medullary thyroid carcinoma","volume":"84","author":"Tisell","year":"1997","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.dld.2003.11.018_BIB40","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/jc.83.7.2417","article-title":"Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma","volume":"88","author":"Mato","year":"1998","journal-title":"J. Clin. Metab. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.2001.01175.x","article-title":"Immunohistochemical detection of somatostatin receptor types 1\u20135 in medullary thyroid carcinoma of the thyroid","volume":"54","author":"Papotti","year":"2001","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcp\/95.3.300","article-title":"Medullary thyroid cancer. An immunohistochemical and humeral study using six separate antigens","volume":"95","author":"Pacini","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.dld.2003.11.018_BIB43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1210\/jcem-51-4-857","article-title":"Immunohistological studies of medullary thyroid carcinoma and C cell hyperplasia","volume":"51","author":"Deftos","year":"1980","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/1097-0142(19890315)63:6<1189::AID-CNCR2820630625>3.0.CO;2-J","article-title":"Somatostatin in medullary thyroid cancer. In vitro and in vivo studies","volume":"63","author":"Pacini","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2003.11.018_BIB45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000226755","article-title":"Plasma somatostatin activity in medullary thyroid cancer of the thyroid","volume":"46","author":"Neradilova","year":"1989","journal-title":"Oncology"},{"key":"10.1016\/j.dld.2003.11.018_BIB46","first-page":"1907","article-title":"Indium-111-DTPA-D-Phe-1-Octreotide and Technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma","volume":"36","author":"Kurtaran","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s002590050296","article-title":"Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings","volume":"25","author":"Adams","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB48","unstructured":"Libroia A, Verga U, Di Sacco G, Muratori F. The possible role of SMS 201-995 in the treatment of metastatic medullary thyroid carcinoma. In: Proceeding of the 71st Annual Meeting of the Endocrine Society. Seattle; 1989. p. 1429."},{"key":"10.1016\/j.dld.2003.11.018_BIB49","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.dld.2003.11.018_BIB50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodinamic effects","volume":"S3","author":"Harris","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.dld.2003.11.018_BIB51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0026-0495(92)90024-5","article-title":"From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics","volume":"41","author":"Marbach","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.dld.2003.11.018_BIB52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","article-title":"Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide","volume":"33","author":"Mahler","year":"1990","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2265.1992.tb00955.x","article-title":"Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma","volume":"36","author":"Modigliani","year":"1992","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.dld.2003.11.018_BIB54","first-page":"44","article-title":"The use of octreotide in the treatment of medullary thyroid carcinoma","volume":"27","author":"Raue","year":"1992","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.dld.2003.11.018_BIB55","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<1114::AID-CNCR23>3.0.CO;2-4","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of recombinant Interferon \u03b1-2b and Octreotide","volume":"78","author":"Lupoli","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2003.11.018_BIB56","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1210\/jc.85.3.983","article-title":"Slow release lanreotide in combination with Interferon-a2b in the treatment of symptomatic advanced medullary thyroid carcinoma","volume":"85","author":"Vitale","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB57","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1210\/jc.86.5.2161","article-title":"Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT","volume":"86","author":"Zatelli","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.dld.2003.11.018_BIB58","unstructured":"Leong SS, Horoszewicz JS, Shimaoka K. A new cell line for study of human medullary carcinoma. In: Andreoli M, editor. Advances in thyroid neoplasia. Rome: Field educational; 1981. p. 95\u2013108."},{"key":"10.1016\/j.dld.2003.11.018_BIB59","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0165-4608(94)00185-E","article-title":"Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines","volume":"80","author":"Cooley","year":"1995","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.dld.2003.11.018_BIB60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-2002-32134","article-title":"Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT","volume":"34","author":"Zatelli","year":"2002","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.dld.2003.11.018_BIB61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0006-291X(02)02307-0","article-title":"Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line","volume":"297","author":"Zatelli","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865803006601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865803006601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T22:22:46Z","timestamp":1550269366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865803006601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":61,"alternative-id":["S1590865803006601"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2003.11.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}